CRISPR Therapeutics AG (CRSP) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Get detailed CRISPR Therapeutics AG (CRSP) stock forecast for 2025, monthly, along with long-term CRSP price prediction from 2025 to 2050. Look at historical stock performance, analyst recommendations (Buy, Sell, or Hold), and the latest CRISPR Therapeutics AG headlines.
1 Month Prediction
$114.11 [129.50%]
3 Month Prediction
$94.79 [90.65%]
6 Month Prediction
$88.79 [78.57%]
1 Year Prediction
$114.03 [129.35%]
3 Year Prediction
$114.51 [130.30%]
5 Year Prediction
$101.48 [104.10%]
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company based in Zug, Switzerland. The company was founded in 2013 by Emmanuelle Charpentier, Shaun Foy, and Rodger Novak. The company develops gene-based medicines using CRISPR/Cas9 technology to treat serious diseases.
Their lead therapy, Casgevy treats sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). It works by editing patients' cells to produce healthy red blood cells, and eliminates the need for regular transfusions.
CRISPR Therapeutics has a wholly-owned subsidiary in the U.S. with operations in Cambridge, Massachusetts, and offices in San Francisco and London.
CRISPR Therapeutics AG (CRSP) Historical Performance
IPO Date
CRISPR Therapeutics AG (NGM:CRSP) went public on 18 October, 2016.
Change
Since inception, CRSP has increased by 172.44%. In the last 5 years, CRSP has risen from $42.41 to $49.72, a minor 17.24% increase since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $165.70 and a low of $38.93.
52 Week Range
$36.52
$91.1
The current price $49.72 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
CRSP Stock Price History
Based on CRSP stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the CRSP stock has fallen from $42.41 - $153.11 to $41.59 - $49.72, which is down -4.75%. Currently, the stock follows downward trend.
Here, we have calculated stock range of CRSP, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $42.41 - $153.11 | $80.79 | 68.52 | 1 Year Change |
| 2021 | $75.78 - $165.7 | $119.12 | 148.48 | 2 Year Change |
| 2022 | $40.65 - $75.0 | $59.13 | 23.34 | 3 Year Change |
| 2023 | $38.93 - $66.73 | $52.97 | 10.49 | 4 Year Change |
| 2024 | $39.36 - $84.22 | $55.42 | 15.6 | 5 Year Change |
| 2025 | $41.59 - $49.72 | $45.66 | -4.75 | 6 Year Change |
CRSP Price Performance
6-Month Performance
CRSP stock jumped by 5.83% in the last six months.
1-Year Performance
The stock has trended downwards by 27.05% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 20.79%.
5-Year Performance
In the last 5 years, the stock has gone up by 17.24%.
According to CRISPR Therapeutics AG's historical data, below graph gives us the exact picture of how the CRSP stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 2 years and a decline in 3 years.
2020
151.39% ↑
2021
50.51% ↓
2022
46.36% ↓
2023
54.00% ↑
2024
37.12% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
CRISPR Therapeutics AG (CRSP) Financials & Stock Analysis
Total Revenue
Annual Revenue: $35.00 M (1Y)
Revenue for trailing 12 months decreased 0.00% year over year from 31st December, 2024.
Market Capitalization
CRISPR Therapeutics AG has a market capitalization of $4.26B, which places CRSP in the mid-cap category.
Fundamental Analysis
EPS: $nan (Q4), $-4.34 (1Y)
EPS decreased nan% since last quarter, and increased 123.71% since last year.
Net Income: $-37.31 M (Q4), $-366.25 M (1Y)
Net Income decreased 56.59% since last quarter, and increased 138.43% since last year.
Free Cash Flow: $-50.28 M (Q4), $-144.68 M (1Y)
Free Cash Flow decreased N/A since last quarter, and decreased 46.88% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for CRSP stock. These indicators help you understand CRISPR Therapeutics AG's financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for CRSP stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $42.05 |
| SMA50 | $42.73 |
| SMA200 | $49.52 |
| RSI | 70.88 |
| Beta | 1.67 |
SMA20 < Current Price
This signals CRSP stock is in short-term bullish momentum.
SMA50 < Current Price
This signals CRSP stock is in mid-term bullish momentum.
SMA200 < Current Price
This signals CRSP stock is in long-term bullish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for CRSP stock is Bullish. Out of all indicators, 5 indicates bullish signals, 3 signals bearish trends and 1 gives neutral trends. The CRSP stock forecast was last updated on 18 February, 2025.
CRISPR Therapeutics AG (CRSP) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $93.19 by the end of 2025, and can reach around $106.05 to $64.66 in 2026. And, the long-term forecast suggests that the stock may further jump to $102.87 - $93.03 in 2028, and $61.15 - $86.77 by 2031. So, the CRSP stock shows a strong upward trend in the next several years.
Short-term CRSP Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-03 | $114.11 | 129.51% |
| 2025-04 | $96.05 | 93.18% |
| 2025-05 | $94.79 | 90.65% |
| 2025-06 | $94.53 | 90.12% |
| 2025-07 | $97.74 | 96.58% |
| 2025-08 | $88.79 | 78.58% |
| 2025-09 | $79.35 | 59.59% |
| 2025-10 | $70.53 | 41.85% |
| 2025-11 | $97.58 | 96.26% |
| 2025-12 | $93.19 | 87.43% |
In 2025, the CRSP stock price is expected to fluctuate between $70.53 and $114.11. According to the monthly forecast, the stock could rise to $93.19 by December 2024. If compared to the CRSP's current price, the stock could gain 87.43% by the end of this year.
Long-term CRSP Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $106.05 | $105.77 | $64.66 | 30.05% |
| 2027 | $103.14 | $95.07 | $62.39 | 25.48% |
| 2028 | $102.87 | $111.35 | $93.03 | 87.11% |
| 2029 | $44.08 | $78.36 | $54.86 | 10.34% |
| 2030 | $97.02 | $85.21 | $35.00 | -29.61% |
| 2031 | $61.15 | $47.73 | $86.77 | 74.52% |
| 2032 | $63.45 | $47.80 | $58.78 | 18.22% |
| 2033 | $57.16 | $76.94 | $72.19 | 45.19% |
| 2034 | $80.23 | $46.46 | $40.68 | -18.18% |
| 2035 | $29.79 | $50.57 | $55.60 | 11.83% |
| 2036 | $43.98 | $50.95 | $38.00 | -23.57% |
| 2037 | $26.36 | $56.35 | $41.09 | -17.36% |
| 2038 | $35.64 | $38.05 | $31.20 | -37.25% |
| 2039 | $36.94 | $31.69 | $37.99 | -23.59% |
| 2040 | $30.90 | $40.38 | $28.77 | -42.14% |
| 2041 | $16.12 | $47.79 | $14.67 | -70.49% |
| 2042 | $18.66 | $25.89 | $13.53 | -72.79% |
| 2043 | $11.17 | $23.80 | $5.53 | -88.88% |
| 2044 | $5.77 | $13.49 | $0.61 | -98.77% |
| 2045 | $1.16 | $10.85 | $1.10 | -97.79% |
| 2046 | $1.10 | $7.31 | $0.77 | -98.45% |
| 2047 | $0.96 | $0.98 | $0.76 | -98.47% |
| 2048 | $0.99 | $0.98 | $0.64 | -98.71% |
| 2049 | $0.87 | $1.02 | $1.28 | -97.43% |
| 2050 | $1.25 | $1.16 | $0.70 | -98.59% |
| 2051 | $0.86 | $0.89 | $0.84 | -98.31% |
CRISPR Therapeutics AG (CRSP) Stock Price Prediction & Forecast 2025
At the start of 2025, the CRSP stock was at $41.59. Today, it is trading at $49.72, which is 19.55% increase from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $93.19 by December 2025 with a 87.43% change.
CRISPR Therapeutics AG (CRSP) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the CRSP stock. During this period, the CRSP's price is forecasted to shift from $106.05 to $35.00, which is -67.00% loss.
In 2026, the stock would possibly open at $106.05, descends to $105.77 by mid-year, and wraps up at $64.66, reflecting a 30.05% increase from today's price. Further moving to 2030, the stock can kick off the year at $97.02, drop to $85.21 by mid-year, and finish at $35.00, which is -29.61% change from current price.
CRISPR Therapeutics AG (CRSP) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $61.15 to $28.77, which is down 74.51%
In 2031, we can expect CRSP to fluctuate between $61.15 and $86.77, a shift indicating a 74.51% gain by year-end compared to current price. And Until 2040, CRSP can likely vary from $28.77 to $30.90. By the end of 2040, the stock could record a -42.14% fall from today's stock price.
CRISPR Therapeutics AG (CRSP) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the CRSP stock can see an a downturn from $16.12 to $0.70 in this period. In 2041, the stock can experience a high of $47.79 by mid-year, closing the year at $14.67. This results in a -3.87% decrease from today.
Moving towards the end of 2050, CRSP is projected to open the year at $1.25. The stock may dip to $1.16 during mid-year and finish the year at $0.70. Compared to the stock's current price, this translates to an overall loss of -98.58% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
CRSP Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | - | $5.52 | 73.58% ▲ | $179.37 ▲ |
| ADTX | Aditxt, Inc. | - | $0.07 | -34.58% ▼ | $1328.57 ▲ |
| GALT | Galectin Therapeutics Inc. | - | $1.41 | 12.80% ▲ | $268.23 ▲ |
| MBRX | Moleculin Biotech, Inc. | - | $2.18 | 44.37% ▲ | $336.52 ▲ |
| MNMD | Mind Medicine (MindMed) Inc. | - | $9.89 | 45.66% ▲ | $96.36 ▲ |
Last updated Feb 18 at 6:40 PM
CRSP : Buy, Sell Or Hold?
Analyst Ratings
Based on 28 analysts, 5 rated as a strong buy, 12 recommended a buy, 10 suggested a hold, 1 advised a sell, and 0 indicated a strong sell.Three months ago, out of 28 analysts, 4 analysts gave a strong buy rating, 10 a buy rating, 11 a hold rating, 2 advised selling, and 1 suggested a strong sell.So, according to analyst ratings, the recommendation for CRSP stock is Buy.
Expert Analysis
According to CRSP short-term and long-term forecast, CRISPR Therapeutics AG shares are projected to go down by 98.59%, and reach a value of $0.70 per share by 2050.
As per technical analysis, indicators show a Bullish sentiment, while Fear & Greed Index stands at 42.857142857142854, which signals Fear. Also, CRSP has recorded 10/30 green days, which reflects a 45.45454545454545% positivity rate with a price volatility of 0.04%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that CRSP stock is undervalued. So, Based on CRSP prediction and analysis, it may be the best time to hold CRSP stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "CRSP” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.